These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 32417940)

  • 21. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
    Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
    Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
    Mondello P; Steiner N; Willenbacher W; Wasle I; Zaja F; Zambello R; Visentin A; Mauro E; Ferrero S; Ghione P; Pitini V; Cuzzocrea S; Mian M
    Ann Hematol; 2016 Jun; 95(7):1107-14. PubMed ID: 27103007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.
    Hill BT; Nastoupil L; Winter AM; Becnel MR; Cerhan JR; Habermann TM; Link BK; Maurer MJ; Fakhri B; Reddy P; Smith SD; Mukhija D; Jagadeesh D; Desai A; Alderuccio JP; Lossos IS; Mehra P; Portell CA; Goldman ML; Calzada O; Cohen JB; Hussain MJ; Ghosh N; Caimi P; Tiutan T; Martin P; Kodali A; Evens AM; Kahl BS
    Br J Haematol; 2019 Feb; 184(4):524-535. PubMed ID: 30575016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.
    Wilder DD; Ogden JL; Jain VK
    Clin Lymphoma; 2002 Mar; 2(4):229-37. PubMed ID: 11970762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
    Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
    Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
    Hainsworth JD; Litchy S; Morrissey LH; Andrews MB; Grimaldi M; McCarty M; Greco FA
    J Clin Oncol; 2005 Mar; 23(7):1500-6. PubMed ID: 15632411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.
    Press OW; Unger JM; Braziel RM; Maloney DG; Miller TP; Leblanc M; Fisher RI;
    J Clin Oncol; 2006 Sep; 24(25):4143-9. PubMed ID: 16896003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.
    Kelly JL; Salles G; Goldman B; Fisher RI; Brice P; Press O; Casasnovas O; Maloney DG; Soubeyran P; Rimsza L; Haioun C; Xerri L; LeBlanc M; Tilly H; Friedberg JW
    J Clin Oncol; 2015 May; 33(13):1482-90. PubMed ID: 25823738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496).
    Barta SK; Li H; Hochster HS; Hong F; Weller E; Gascoyne RD; Habermann TM; Gordon LI; Colocci N; Bengtson EM; Horning SJ; Kahl BS
    Cancer; 2016 Oct; 122(19):2996-3004. PubMed ID: 27351685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term survival and prognostic analysis of advanced stage follicular lymphoma in the rituximab era: A China single-center retrospective study.
    Zhou Y; Qin Y; He X; Liu P; Yang J; Zhou L; Zhou S; Gui L; Yang S; Zhang C; Shi Y
    Asia Pac J Clin Oncol; 2021 Jun; 17(3):289-299. PubMed ID: 32970914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.
    Luminari S; Ferrari A; Manni M; Dondi A; Chiarenza A; Merli F; Rusconi C; Tarantino V; Tucci A; Vitolo U; Kovalchuk S; Angelucci E; Pulsoni A; Arcaini L; Angrilli F; Gaidano G; Stelitano C; Bertoldero G; Cascavilla N; Salvi F; Ferreri AJM; Vallisa D; Marcheselli L; Federico M
    J Clin Oncol; 2018 Mar; 36(7):689-696. PubMed ID: 29095677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Watanabe R; Tomita N; Kishimoto K; Koyama S; Ogusa E; Ishii Y; Miyashita K; Matsuura S; Fujisawa S; Hattori Y; Takasaki H; Fujita A; Ohshima R; Kuwabara H; Hashimoto C; Fujimaki K; Sakai R; Ishigatsubo Y
    Leuk Res; 2013 Oct; 37(10):1208-12. PubMed ID: 23927994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.
    Rossi D; Bruscaggin A; La Cava P; Galimberti S; Ciabatti E; Luminari S; Rigacci L; Tucci A; Pulsoni A; Bertoldero G; Vallisa D; Rusconi C; Spina M; Arcaini L; Angrilli F; Stelitano C; Merli F; Gaidano G; Federico M; Palumbo GA
    Haematologica; 2015 Apr; 100(4):517-24. PubMed ID: 25596266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma.
    Freeman CL; Kridel R; Moccia AA; Savage KJ; Villa DR; Scott DW; Gerrie AS; Ferguson D; Cafferty F; Slack GW; Farinha P; Skinnider B; Connors JM; Sehn LH
    Blood; 2019 Aug; 134(9):761-764. PubMed ID: 31300404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome.
    Buske C; Hoster E; Dreyling M; Hasford J; Unterhalt M; Hiddemann W
    Blood; 2006 Sep; 108(5):1504-8. PubMed ID: 16690968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baseline correlations and prognostic impact of serum monoclonal proteins in follicular lymphoma.
    Mozas P; Rivero A; Rivas-Delgado A; Fabregat A; Piñeyroa JA; Correa JG; Nadeu F; Oliver A; Bataller A; Giné E; Delgado J; Villamor N; Cibeira MT; Fernández de Larrea C; Rosiñol L; Campo E; Aróstegui JI; Bladé J; Magnano L; López-Guillermo A
    Br J Haematol; 2021 Apr; 193(2):299-306. PubMed ID: 33200406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
    Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
    Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.
    Federico M; Luminari S; Dondi A; Tucci A; Vitolo U; Rigacci L; Di Raimondo F; Carella AM; Pulsoni A; Merli F; Arcaini L; Angrilli F; Stelitano C; Gaidano G; Dell'olio M; Marcheselli L; Franco V; Galimberti S; Sacchi S; Brugiatelli M
    J Clin Oncol; 2013 Apr; 31(12):1506-13. PubMed ID: 23530110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.